Ipsen Licenses Second ADC via $1B Bet on Foreseen Bio Asset

1. Deal Value: Ipsen has entered into a licensing agreement with Foreseen Biotechnology worth up to $1 billion.
2. ADC Asset: The deal involves a potential first-in-class ADC that targets a novel mechanism.
3. Second ADC Deal: This is Ipsen's second ADC deal this year, following a $900 million deal with Sutro Biopharma in April.
4. Exclusive Global Licensing: Ipsen has secured an exclusive global licensing agreement for the ADC asset.
5. Foreseen Biotechnology: Foreseen Biotechnology has received significant backing, with $3.6 billion from investors.